AstraZeneca PLC Second quarter and half year results 2011

Thursday, 28 July 2011

David Brennan, Chief Executive Officer said:

"Despite the anticipated impact of generic competition and government pricing interventions in the quarter, we are able to raise our Core earnings per share guidance and increase our shareholder cash return targets for the full year. The approval of Brilinta in 41 countries around the world, most recently in the US, demonstrates our commitment to deliver our global, innovation-driven biopharmaceuticals strategy."


Second quarter and half year results 2011

Announced on Thursday 28 July 2011



View the webcast


  • Corporate and financial